中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (23): 4363-4366.doi: 10.3969/j.issn.1673-8225.2011.23.042

• 干细胞临床实践 clinical practice of stem cells • 上一篇    下一篇

脐带间充质干细胞移植治疗初发1型糖尿病

于文龙1，高  宏2，余霄龙1，王  丽2，阎胜利1，王颜刚1，2   

  1. 青岛大学医学院附属医院，1内分泌科，2中美干细胞中心，山东省青岛市  266003
  • 收稿日期:2010-03-19 修回日期:2010-05-24 出版日期:2011-06-04 发布日期:2011-06-04
  • 通讯作者: 王颜刚，博士，主任医师，博士生导师，青岛大学医学院附属医院内分泌科及干细胞研究中心，山东省青岛市 266003 wangyg1966@yahoo.com.cn
  • 作者简介:于文龙★，男，1983年生，山东省高密市人，汉族，青岛大学医学院附属医院内分泌科在读硕士，主要从事干细胞治疗1型糖尿病的研究。 wenlongyuwenlong@126.com

Umbilical cord mesenchymal stem cells transplantation for newly-onset type 1 diabetes

Yu Wen-long1, Gao Hong2, Yu Xiao-long1, Wang Li2, Yan Sheng-li1, Wang Yan-gang1,2   

  1. 1Department of Endocrine, 2Chinese-American Research Center for Stem Cells, Affiliated Hospital of Qingdao University Medical College, Qingdao  266003, Shandong Province, China
  • Received:2010-03-19 Revised:2010-05-24 Online:2011-06-04 Published:2011-06-04
  • Contact: Wang Yan-gang, Doctor, Chief physician, Doctoral supervisor, Department of Endocrine, Chinese-American Research Center for Stem Cells, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China wangyg1966@yahoo.com.cn
  • About author:Yu Wen-long★, Studying for master’s degree, Department of Endocrine, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China wenlongyuwenlong@126.com

PDF

838

被引次数

16

摘要：

背景：研究证实，新诊断的1型糖尿病患者，接受自体造血干细胞治疗后，绝大多数患者胰岛β细胞功能增强，不依赖胰岛素的时间也延长。
目的：观察人脐带间充质干细胞移植治疗初发1型糖尿病的临床疗效。
方法：选择12例病程<3个月的初发1型糖尿病患者，其中6例行人脐带间充质干细胞和胰岛素治疗，另外6例行单纯胰岛素治疗。移植前及移植9个月后分别监测空腹及餐后血糖、胰岛素用量、C肽、HbA1c的变化和记录不良反应。
结果与结论：随访9个月，干细胞治疗组的空腹血糖，糖化血红蛋白及C肽水平都有明显的改善，而对照组C肽水平明显下降，其他指标变化不明显。提示，人脐带间充质干细胞治疗初发1型糖尿病疗效良好。

关键词: 人脐带间充质干细胞, 移植, 1型糖尿病, C肽, HbA1c

Abstract:

BACKGROUND: Autologous hematopoietic stem cells transplantation can enhance function of beta cells of islet and prolong time independent of insulin.
OBJECTIVE: To observe the clinical efficacy of human umbilical cord mesenchymal stem cells (hUCMSCs) transplantation in treatment of newly-onset type 1 diabetes.
METHODS: A total of 12 patients with newly-onset type 1 diabetes mellitus (less than 3 months) were selected. Six cases were treated by hUCMSCs transplantation and insulin, and the other 6 were treated by insulin alone. Before and 9 months after transplantation, fasting and postprandial blood glucose, insulin dosage, C peptide, HbA1c changes and adverse events were measured.
RESULTS AND CONCLUSION: Patients were followed up for 9 months. Fasting blood glucose, HbA1c and C peptide levels were significantly improved in stem cell therapy group compared with control group. In addition to significantly reduced C peptide levels, other indexes remained unchanged in control group. Results showed that hUCMSCs transplantation has positive effects on treatment of newly-onset type l diabetes.

中图分类号: